You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窝轮》【瑞通认股证牛熊证】美团升穿84元再创新高 中海外升2%挑战50天线 美团最高收回价牛56730 熊54755/ 中海外购28295/ 舜光最高收回价牛55463
阿思达克 10-04 10:35

市场消化美国经济数据转差,并转而憧憬联储局今月减息机会增加,道指隔晚跌逾300点後倒升,收报26201点,升122点(或0.5%)。

恒指昨先跌後升,收报26110点,升67点,今早好淡争持,暂守26000点关口。恒指好仓(牛证及认购权证)昨净流入逾2200万港元(下同),恒指淡仓(熊证及认沽权证)同日净流出逾680万元,反映投资者续博港股短线反弹。昨日恒指牛证街货重货区为收回价25700至25798点,而熊证街货重货区为收回价26400至26499点。

有券商予美团点评(03690)「持有」评级,另投资者继续憧憬公司业务高速增长以及监管机构批准北水买卖。近期强势的美团昨再度破顶,盘中高见83元,收报报82.4元,维持逾1%升幅,多条移动平均线呈上升趋势。美团今早再升,曾升至84.05元之上市高位,14日RSI呈超买水平,下方如能守稳10天线(约79.1元),技术走势仍强。昨有61万元净流出其好仓,淡仓同日则有39万元净流入。

内地将在全国范围内推全面药品集中采购。石药(01093)昨低开於15.5元後逐步回升,以近全日高位16.16元收市,升幅3.32%。今早好淡争持,力守16元,续处主要平均线之上。昨有2万元净流入其好仓,淡仓同日亦有25万元净流入。

有券商指内房九月销售按年增长达29%,属历史次高。中国海外发展(00688)昨曾升穿25元,收市升1.2%於24.9元,重上10天线。今早曾再升逾2%,重返25元之上,但受制20天线,下方留意24.2元支持。昨有57万元净流入其好仓。

澳门十月首两天内地访客入境人次按年增加9.6%,券商普遍预期十月赌收平稳。金沙中国(01928)昨以近全日高位36.3元收市,升1.8%,收复10天线,盘中守35元,暂连升4个交易日。金沙今早略回至36元水平。昨有29万元净流出其好仓,淡仓同日则有16万元净流入。

瑞通相关认股证之选择:

美团轻微价外、中年期购29161,行使价:88.3元,2020年4月到期,实际杠杆:5.3倍

美团价外、中短期沽11021,行使价:70.93元,2020年2月到期,实际杠杆:4.9倍

石药轻微价外、中年期购27547,行使价:17.38元,2020年4月到期,实际杠杆:4.2倍

石药轻微价外、长期沽28344,行使价:14.68元,2020年7月到期,实际杠杆:2.3倍

中海轻微价外、中年期购28295,行使价:26.8元,2020年5月到期,实际杠杆:5.8倍

金沙轻微价外、中短期购19611,行使价:40.88元,2020年1月到期,实际杠杆:9.1倍

腾讯贴价、短期购22645,行使价:334元,2019年12月到期,实际杠杆:11.4倍

腾讯轻微价外、短期沽25605,行使价:306.7元,2019年12月到期,实际杠杆:10.8倍

石药轻微价外、中年期购27547,行使价:17.38元,2020年4月到期,实际杠杆:4.1倍

石药轻微价外、长期沽28344,行使价:14.68元,2020年7月到期,实际杠杆:2.3倍

瑞通相关牛熊证之选择:

恒指牛证54911,收回价:25510点,杠杆比率:33.1倍

恒指熊证56523,收回价:26590点,杠杆比率:39倍

美团场内最高收回价的牛证56730,收回价:78.1元,杠杆比率:8.5倍

美团熊证54755,收回价:88.6元,杠杆比率:8.3倍

石药牛证64267,收回价:10.8元,杠杆比率:2.5倍

金沙牛证67354,收回价:31.8元,杠杆比率:5.6倍

舜光场内最高收回价的牛证55463,收回价:110.8元,杠杆比率:7.5倍

舜光熊证55946,收回价:130.9元,杠杆比率:7.3倍

友邦牛证57802,收回价:70.07元,杠杆比率:12.7倍

友邦熊证56677,收回价:77.9元,杠杆比率:19.2倍重要风险通知

本结构性产品并无抵押品。

结构性产品之价格一般可急升亦可急跌,有可能损失结构性产品之全部或重大部分购买价,阁下对此应有所准备。

阁下投资前应了解产品风险,如有需要应谘询专业建议。~重要声明:

以上资讯由第三方提供,AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告,不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料,本公司亦不负品质保证之责任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account